TABLE 2

Radioactive Retention of 99mTc-Radiopharmaceuticals in Syringes and Needles after 30 Minutes of Incubation

Retention in syringe (%)
RadiopharmaceuticalSyringe brandUndiluted1:3 with saline1:10 with salineRetention in needle (%) (undiluted)
99mTc-pertechnetateA1.3 ± 1.01.5 ± 0.84.8 ± 1.14.5 ± 1.1
B1.9 ± 0.31.1 ± 0.11.4 ± 1.02.9 ± 1.6
99mTc-butedronateA3.6 ± 0.62.1 ± 0.51.6 ± 0.84.3 ± 0.2
B2.6 ± 0.82.2 ± 0.32.1 ± 0.72.0 ± 0.4
99mTc-oxidronateA2.1 ± 1.82.8 ± 1.71.6 ± 0.82.9 ± 1.9
B1.8 ± 1.82.2 ± 0.22.3 ± 0.53.0 ± 1.3
99mTc-medronateA2.4 ± 0.31.4 ± 1.22.1 ± 2.33.9 ± 0.4
B1.7 ± 1.11.1 ± 0.61.8 ± 0.72.4 ± 0.5
99mTc-tetrofosminA6.7 ± 0.85.9 ± 1.84.7 ± 1.86.7 ± 1.0
B6.0 ± 0.33.5 ± 0.83.8 ± 0.73.1 ± 0.4
99mTc-sestamibiA6.9 ± 3.67.3 ± 1.613.0 ± 2.55.2 ± 0.2
B3.3 ± 1.16.3 ± 0.89.0 ± 0.92.5 ± 0.2
99mTc-succimerA10.7 ± 1.49.8 ± 1.96.9 ± 0.213.9 ± 0.2
B13.9 ± 2.014.2 ± 1.119.5 ± 4.36.9 ± 0.2
99mTc-DMSA(V) pentavalentA1.8 ± 0.32.2 ± 0.22.1 ± 1.24.5 ± 0.9
B2.4 ± 0.32.4 ± 0.62.0 ± 0.51.7 ± 0.5